Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma

doi:10.3389/fmolb.2021.736940

	Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma
	Fan, Ying 1,2,3,5; Shan, Qianyun 2,3,4,5; Gong, Jiali 2,3,4,5; Qin, Jing 2,3,5; Lu, Hongyang 1,2,3,4,5
刊名	FRONTIERS IN MOLECULAR BIOSCIENCES
	2021-10-25
卷号	8
关键词	PPLELC clinical characteristics molecular characteristics immunotherapy PD-L1 TMB
DOI	10.3389/fmolb.2021.736940
通讯作者	Lu, Hongyang(luhy@zjcc.org.cn)
英文摘要	Objectives: Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is an extremely rare subtype of non-small cell lung cancer (NSCLC). Currently, there are no established treatment protocols due to rarity of the cancer. Thus, this study aimed to explore the molecular and clinical characteristics of PPLELC. Study design and setting: Data from patients with PPLELC who were admitted to Zhejiang Cancer Hospital from August 2009 to September 2020 were retrospectively collected. Next-generation sequencing was performed to obtain a genomic profile and tumor mutation burden (TMB) value of patients with adequate tissue and divided them into two groups according to the expression level of PD-L1. The correlation of PD-L1 expression and the clinicopathological characteristics was evaluated by Pearson Chi-square test. Kaplan-Meier curves was applied to present the probability of survival between PD-L1 expression level and overall survival (OS). Moreover, the literature on the immunotherapy of advanced PPLELC published in PubMed between 2016 and 2020 were reviewed and the efficacy of immunotherapy were analyzed. Results: A total of 18 patients pathologically diagnosed as PPLELC were included. After a follow-up period of 8.8-138 months, 14 patients survived, three patients died and one patient lost, the median OS was 45.3 months Seven samples (tissue-available) tested by NGS and the median TMB was 2.5 mutations/Mb. 19 somatic mutated genes were recognized and TP53 (43%) and CYLD (43%) were the two most commonly mutated genes. Only seven patients who underwent NGS were tested for PD-L1. Three patients with high PD-L1 expression (PD-L1 >= 50%) and four patients with low PD-L1 expression (PD-L1 <50%) were included. No significant correlation was observed between PD-L1 expression and clinical characteristics (age, gender, smoking status, tumor stage, lymph node metastasis) (p > 0.05) and OS (p = 1). What's more, 10 PPLELC patients involved in previous studies and one patient received nivolumab in the current study were collected retrospectively. 4/11 (36.4%) patients achieved PR, 6/11 (54.5%) patients achieved SD, and 1/11 (9.1%) patients achieved PD and the disease control rate (DCR) was 90.9%. Conclusions: The prognosis of PPLELC is better than that of other NSCLC, and immunotherapy may be a promising treatment to prolong the survival of advanced PPLELC patients. Whether the immunotherapy efficacy of PPLELC can be predicted by PD-L1 and TMB needs further clinical investigation. CYLD genetic alterations may participate in Epstein-Barr virus-mediated tumorigenesis in PPLELC, providing a novel therapeutic target.
资助项目	Zhejiang Province Medical Science and Technology Project[2020ZH001] ; [e20541]
WOS关键词	COMPUTED-TOMOGRAPHY CHARACTERISTICS ; MUTATION STATUS ; PD-1 BLOCKADE ; NIVOLUMAB ; CANCER ; IMMUNOTHERAPY ; EXPRESSION ; FEATURES ; OUTCOMES ; P53
WOS研究方向	Biochemistry & Molecular Biology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000717349500001
资助机构	Zhejiang Province Medical Science and Technology Project
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126542]
专题	中国科学院合肥物质科学研究院
通讯作者	Lu, Hongyang
作者单位	1.Wenzhou Med Univ, Clin Med Coll 1, Wenzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Hosp, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Zhejiang Key Lab Diag & Treatment Technol Thorac, Canc Hosp, Hangzhou, Peoples R China 4.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China 5.Chinese Acad Sci, Inst Basic Med & Canc IMBC, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Fan, Ying,Shan, Qianyun,Gong, Jiali,et al. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma[J]. FRONTIERS IN MOLECULAR BIOSCIENCES,2021,8.
APA	Fan, Ying,Shan, Qianyun,Gong, Jiali,Qin, Jing,&Lu, Hongyang.(2021).Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma.FRONTIERS IN MOLECULAR BIOSCIENCES,8.
MLA	Fan, Ying,et al."Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma".FRONTIERS IN MOLECULAR BIOSCIENCES 8(2021).